Clinical trials: Acute Infection Respiratory
Acute Respiratory Viral Infection
Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old
The multicenter double-blind placebo-controlled randomized in parallel-group. The objective of this study is to evaluate efficacy and safety of Raphamin in the treatment of acute respiratory viral infection (ARVI) in children…
- Trial name
- NCT04918771
- Testing
- Raphamin
- Where
- 29 sites in Russia
- Volunteers
- 435 people
- Sponsor
- Materia Medica Holding
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
Sinusitis
Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children
The investigators objective is to compare short course (5 days) to long course (14 days)antibiotics for the treatment of acute bacterial sinusitis in children.
- Trial name
- NCT01166945
- Testing
- Amoxicillin-Potassium Clavulanate Combination
- Where
- 2 sites in United States
- Volunteers
- 98 people
- Sponsor
- University of Wisconsin, Madison
Covid19, Post-acute COVID-19 Respiratory Disease
LYT-100 in Post-acute COVID-19 Respiratory Disease
This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory…
- Trial name
- NCT04652518
- Testing
- LYT-100
- Where
- 31 sites in United States, Argentina and 6 more
- Volunteers
- 185 people
- Sponsor
- PureTech
COVID-19
AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19
In this first-in-humans dose escalation study, AZD7442 (AZD8895 + AZD1061) will be evaluated for safety, tolerability, pharmacokinetics, and generation of anti-drug antibodies (ADAs).
- Trial name
- NCT04507256
- Testing
- AZD7442
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19, Lung Injury, Acute
SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)
This study will evaluate the safety of a 96-hour intravenous vitamin C infusion protocol (50 mg/kg every 6 hours) in patients with hypoxemia and suspected COVID-19.
- Conditions
- COVID-19, Lung Injury, Acute, Kidney Injury
- Trial name
- NCT04344184
- Testing
- L-ascorbic acid
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Virginia Commonwealth University
Post-COVID-19 Condition, Post-COVID-19 Syndrome
Vortioxetine for Post-COVID-19 Condition
A randomized, double-blinded, placebo-controlled trial will be conducted to evaluate vortioxetine, an antidepressant with established pro-cognitive properties, for the treatment of cognitive deficits which develop during or after…
- Conditions
- Post-COVID-19 Condition, Post-COVID-19 Syndrome, Cognitive Impairment
- Trial name
- NCT05047952
- Testing
- Vortioxetine
- Where
- Canada
- Volunteers
- 149 people
- Sponsor
- Brain and Cognition Discovery Foundation
Covid-19
Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19)
A comparison of a direct antigen test for SARS-CoV-2 obtained by mid-turbinate swab with the reference standard rt-PCR test obtained by nasopharyngeal swab in outpatients with symptoms compatible with COVID-19.
- Trial name
- NCT04610489
- Testing
- Quidel Sofia SARS Antigen FIA
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Carilion Clinic
Covid19
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
- Trial name
- ACTIV-4A (NCT04505774)
- Testing
- theraputic heparin, prophylactic heparin, P2Y12
- Where
- 101 sites in United States, Brazil and 2 more
- Volunteers
- 3,591 people
- Sponsor
- Matthew Neal MD
Influenza
Statin Therapy in Acute Influenza
Influenza (the 'flu') is a common virus infecting approximately 5-20% of the population in the United States and causing as many as 500,000 deaths worldwide each year.
- Trial name
- NCT02056340
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Beth Israel Deaconess Medical Center
Acute Respiratory Distress Syndrome, Sepsis
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
This study is a multi-center, randomized, partially double-blind, and placebo-controlled Phase Ib clinical trial of inhaled CO (iCO) for the treatment of sepsis-induced acute respiratory distress syndrome (ARDS).
- Trial name
- NCT04870125
- Testing
- Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%), Inhaled Medical air
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Brigham and Women's Hospital
Acute Respiratory Distress Syndrome, COVID-19
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
- Trial name
- NCT04537806
- Testing
- Brexanolone
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sage Therapeutics
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially…
- Trial name
- regARDS (NCT05027815)
- Testing
- Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Jeffrey Bluestone
COVID-19, Sars-CoV2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe…
- Conditions
- COVID-19, Sars-CoV2, Pneumonia
- Trial name
- NCT04463004
- Testing
- Mavrilimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virginia Commonwealth University
COVID-19
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
Phase 1 To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 Phase 2 To evaluate the…
- Trial name
- NCT04425629
- Testing
- casirivimab+imdevimab combination therapy
- Where
- 114 sites in United States, Mexico and 1 more
- Volunteers
- 10,078 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy
Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.
The purpose of the AcRIS study is to obtain data to characterize the relationship between symptoms and voice features for (reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome…
- Trial name
- NCT04748445
- Testing
- SARS-CoV-2/Influenza/RSV RT-PCR
- Where
- United States
- Volunteers
- 9,151 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2 Infection
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19.
- Trial name
- NCT05263908
- Testing
- nirmatrelvir / ritonavir
- Where
- Japan
- Volunteers
- 3,346 people
- Sponsor
- Pfizer
Long COVID, Long Covid19
RECOVER-AUTONOMIC Platform Protocol
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent…
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Trial name
- NCT06305780
- Testing
- IVIG + Coordinated Care, Ivabradine + Coordinated Care, IVIG + Usual Care
- Where
- 50 sites in United States
- Volunteers
- 381 people
- Sponsor
- Kanecia Obie Zimmerman
Preventive Medicine
Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI
The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children…
- Trial name
- NCT03301155
- Testing
- Anaferon for children
- Where
- 33 sites in Russia, Uzbekistan
- Volunteers
- 1,036 people, healthy volunteers welcome
- Sponsor
- Materia Medica Holding
Acute Respiratory Distress Syndrome, Coronavirus Infection
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04478071
- Testing
- vadadustat
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- The University of Texas Health Science Center, Houston